Pharma giants Sanofi and Novartis came in at No. 7 and 17, respectively, in Time magazine’s “Most Sustainable Companies of 2024” rankings. Overall, nearly 40 of the 500 companies on the list fell under the category of Chemicals, Drugs & Biotechnology. Other large pharma companies making it into the top half of the 500 included…

Veranova recently announced that it will invest $30 million in its Devens, Massachusetts facility to expand its antibody-drug conjugate (ADC) and highly potent compound development and manufacturing capabilities The Wayne, Pennsylvania–based company — a specialist in making active pharmaceutical ingredients — said the investment in the Devens plant will build upon the site’s existing development…

Novo Nordisk today announced plans to invest $4.1 billion to build a new manufacturing facility in North Carolina. The Denmark-based company will build a second fill and finishing manufacturing facility in Clayton, North Carolina, to grow its ability to produce current and future injectable treatments for people with obesity and other serious chronic diseases. Novo…

Emergent BioSolutions this week announced it entered into a definitive agreement to sell its Baltimore-Camden drug product facility. The Gaithersburg, Maryland-based company will sell the facility to an affiliate of Bora Pharmaceuticals for approximately $30 million. Emergent’s Camden site is part of the company’s Contract Development and Manufacturing Organization (CDMO) and has clinical and commercial…

Thermo Fisher Scientific has expanded its clinical research laboratory building at its good manufacturing practices (GMP) lab in Middleton, Wisconsin. The new $58 million investment adds 72,500 sq ft. to the company’s footprint and increases the site’s chemistry, manufacturing, and control analytical capabilities for biopharmaceutical therapy development. “As research in biopharmaceutical therapies continues to rapidly…

Kyowa Kirin announced that its board of directors approved plans to invest up to $530 million to build a new pharmaceutical manufacturing facility. The Japan-based company plans to build a new, state-of-the-art facility in Sanford, North Carolina. It expects the 171,700-square-foot, two-reactor facility to accelerate the development and production of biologic therapies for rare and…

Vetter recently announced it is expanding its development services sites in the U.S. and is planning for major investments in Germany. The company announced plans to move and expand its Development Services site from Skokie, Illinois, to Des Plaines, Illinois. It plans to invest majorly in its commercial business in Saarland, Germany, to complement its…

Molecular Devices recently announced it opened its custom-built bioanalytical site in the U.K. The new facility is based in Cardiff, Wales, and is custom-built for the company’s bioprocess workflow and unique bioreactor technology. Molecular Devices’ biotechnology allows pharmaceutical companies to manufacture patient-derived organoids (PDOs) at scale in a quality-controlled manner. “Molecular Devices is the only…

Merck KGaA, Darmstadt, Germany announced that it opened its newly expanded Life Science distribution center in Schnelldorf. The company invested €180 million and added 25,000 square meters in space to the site, nearly doubling its size. It now features a manual down filling operation and additional space for the distribution of products to laboratories and…

French pharma giant Sanofi recently opened a pediatric and adult vaccine manufacturing facility on its Toronto campus. The facility officially opened on May 30. According to Sanofi, the new plant significantly increases its capacity to meet growing demand in Canada and around the world for pediatric and adult vaccines for pertussis (whooping cough), diphtheria and…